{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:01:47Z","timestamp":1771228907591,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.7759\/cureus.103688","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:09:02Z","timestamp":1771225742000},"source":"Crossref","is-referenced-by-count":0,"title":["Steroid-Refractory Pembrolizumab-Induced Haemophagocytic Lymphohistiocytosis (HLH) Successfully Treated With Anakinra: A Case Report"],"prefix":"10.7759","author":[{"given":"Praveen Kumar","family":"Kaudlay Sathyanarayana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandathil","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffi","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeeka","family":"Dilhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310684","article-title":"Investigation of molecular interactions mechanism of pembrolizumab and PD-1","volume":"24","author":"Wang S","year":"2023","unstructured":"Wang S, Khan FI. Investigation of molecular interactions mechanism of pembrolizumab and PD-1. Int J Mol Sci. 2023, 24:10.3390\/ijms241310684","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin Q","year":"2023","unstructured":"Yin Q, Wu L, Han L, et al.. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023, 14:10.3389\/fimmu.2023.1167975","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113530","article-title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","volume":"199","author":"Brahmer JR","year":"2024","unstructured":"Brahmer JR, Long GV, Hamid O, et al.. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024, 199:10.1016\/j.ejca.2024.113530","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter JI","year":"2025","unstructured":"Henter JI. Hemophagocytic lymphohistiocytosis. N Engl J Med. 2025, 392:584-98. 10.1056\/NEJMra2314005","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02941-3","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore","volume":"24","author":"Knaak C","year":"2020","unstructured":"Knaak C, Nyvlt P, Schuster FS, et al.. Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care. 2020, 24:244. 10.1186\/s13054-020-02941-3","journal-title":"Crit Care"},{"key":"ref7","unstructured":"ECOG performance status scale. Accessed. January 20, 2026: https:\/\/ecog-acrin.org\/resources\/ecog-performance-status\/."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet L","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al.. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014, 66:2613-20. 10.1002\/art.38690","journal-title":"Arthritis Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95260","article-title":"Nivolumab-induced hemophagocytic lymphohistiocytosis (HLH) in a patient with metastatic melanoma: a case report and literature review","volume":"17","author":"Virdi RK","year":"2025","unstructured":"Virdi RK, Hussain U, Bitran J. Nivolumab-induced hemophagocytic lymphohistiocytosis (HLH) in a patient with metastatic melanoma: a case report and literature review. Cureus. 2025, 17:10.7759\/cureus.95260","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda R","year":"2019","unstructured":"Noseda R, Bertoli R, M\u00fcller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019, 7:117. 10.1186\/s40425-019-0598-9","journal-title":"J Immunother Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2024.102896","article-title":"Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: a review of the current knowledge and future directions","volume":"110","author":"Walmsley CS","year":"2025","unstructured":"Walmsley CS, Schoepflin Z, De Brabandt C, Rangachari D, Berwick S, Patell R. Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: a review of the current knowledge and future directions. Blood Cells Mol Dis. 2025, 110:10.1016\/j.bcmd.2024.102896","journal-title":"Blood Cells Mol Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot JM","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A, et al.. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. Eur J Cancer. 2019, 122:72-90. 10.1016\/j.ejca.2019.07.014","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00273-4","article-title":"Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline","volume":"6","author":"Cox MF","year":"2024","unstructured":"Cox MF, Mackenzie S, Low R, et al.. Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline. Lancet Rheumatol. 2024, 6:51-62. 10.1016\/S2665-9913(23)00273-4","journal-title":"Lancet Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter JI","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al.. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-31. 10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01404-0","article-title":"Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis","volume":"41","author":"Wang C","year":"2023","unstructured":"Wang C, Sun W, Li Z, Wu T, Fang W. Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis. Invest New Drugs. 2023, 41:834-41. 10.1007\/s10637-023-01404-0","journal-title":"Invest New Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis EJ","year":"2019","unstructured":"Davis EJ, Salem JE, Young A, et al.. Hematologic complications of immune checkpoint inhibitors. Oncologist. 2019, 24:584-8. 10.1634\/theoncologist.2018-0574","journal-title":"Oncologist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e P","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, et al.. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019, 133:2465-77. 10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-154","article-title":"Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review","volume":"11","author":"Wei Y","year":"2022","unstructured":"Wei Y, He W, Sun W, et al.. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review. Transl Cancer Res. 2022, 11:2960-6. 10.21037\/tcr-22-154","journal-title":"Transl Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/reports8040256","article-title":"Pembrolizumab-associated hemophagocytic lymphohistiocytosis in clear cell renal carcinoma: case report and literature review","volume":"8","author":"Pinto Valdivia R","year":"2025","unstructured":"Pinto Valdivia R, Posado-Dom\u00ednguez L, Iglesias ME, Ant\u00fanez Plaza P, Fonseca-S\u00e1nchez E. Pembrolizumab-associated hemophagocytic lymphohistiocytosis in clear cell renal carcinoma: case report and literature review. Reports (MDPI). 2025, 8:10.3390\/reports8040256","journal-title":"Reports (MDPI)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-025-05302-2","article-title":"Treatment-refractory immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in the setting of adjuvant pembrolizumab for resected stage IIC melanoma: a case report","volume":"19","author":"Chow KV","year":"2025","unstructured":"Chow KV, Mui K, Hunt S, Gan CL. Treatment-refractory immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in the setting of adjuvant pembrolizumab for resected stage IIC melanoma: a case report. J Med Case Rep. 2025, 19:535. 10.1186\/s13256-025-05302-2","journal-title":"J Med Case Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory B","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, et al.. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016, 44:275-81. 10.1097\/CCM.0000000000001402","journal-title":"Crit Care Med"},{"key":"ref22","unstructured":"Anakinra for haemophagocytic lymphohistiocytosis for adults and children in all ages. (2021). Accessed. January 20, 2026: https:\/\/www.england.nhs.uk\/publication\/anakinra-for-haemophagocytic-lymphohistiocytosis-for-adults-and-children-in-al...."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195799","article-title":"Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases","volume":"11","author":"Baverez C","year":"2022","unstructured":"Baverez C, Grall M, Gerfaud-Valentin M, et al.. Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases. J Clin Med. 2022, 11:10.3390\/jcm11195799","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14029","article-title":"Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review","volume":"111","author":"Charlesworth JE","year":"2023","unstructured":"Charlesworth JE, Kavirayani A. Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review. Eur J Haematol. 2023, 111:458-76. 10.1111\/ejh.14029","journal-title":"Eur J Haematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001555","article-title":"Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review","volume":"35","author":"Salazar Gonz\u00e1lez F","year":"2024","unstructured":"Salazar Gonz\u00e1lez F, Qui\u00f1ones Palacios CA, Manzaneque Gord\u00f3n A, Mazarico Gallego JM, D\u00edaz A, Molas Ferrer G. Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review. Anticancer Drugs. 2024, 35:284-7. 10.1097\/CAD.0000000000001555","journal-title":"Anticancer Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455928-steroid-refractory-pembrolizumab-induced-haemophagocytic-lymphohistiocytosis-hlh-successfully-treated-with-anakinra-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:09:04Z","timestamp":1771225744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455928-steroid-refractory-pembrolizumab-induced-haemophagocytic-lymphohistiocytosis-hlh-successfully-treated-with-anakinra-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.103688","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}